读者在线:用户名 密码
首页期刊简介投稿须知期刊目录专家风采编委会特约编委特邀顾问广告发行联系我们

喜报

《中华消化病与影像杂志(电子版)》

被中国科技核心期刊(中国科技论文统计源期刊)收录




刊物信息more
期刊名称:中华消化病与影像杂志
              (电子版)
主管单位:中华人民共和国国家
           卫生健康委员会
主办单位:中华医学会
承办单位:山东省第二人民医院(山东省耳鼻喉医院)
总 编 辑: 王宝成   孙钢
 
网 址http://www.zhxhbyyxzz.com
地 址
济南市槐荫区段兴西路4号
        
  中华消化病与影像杂志( 电子版)
编辑部
电 话:0531-83086377
    

邮政编码:250022

电子邮箱:zhxhbyyxzz@126.com
国际标准刊号:ISSN 2095-2015
国内统一刊号:CN 11-9312/R
访问统计
您是第 5844523位浏览者
  您当前的位置:首页 >> 正文

乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究 [中文引用][英文引用]

Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan

作者(英文): 
单位(英文): 
分类号:
出版年·卷·期(页码):2023·1·第5期(317-321)
DOI: 10.3877/cma.j.issn.2095-2015.2023.05.009
-----摘要:-------------------------------------------------------------------------------------------

 【摘要】目的:分析对比伊立替康化疗方案与伊立替康联合乌苯美司治疗方案二线治疗晚期胃癌的临床疗效与安全性。方法:回顾性分析2018年1月至2022年1月华中科技大学同济医学院附属梨园医院收治的104例晚期胃癌患者的临床资料,根据患者采取的治疗方案不同,将所有患者分为对照组61例(伊立替康化疗方案)和观察组43例(伊立替康联合乌苯美司治疗方案),两组均以21天为1个周期,共治疗2个周期。比较两组患者在治疗后1周的短期临床疗效、治疗前后外周血中的CD3+、CD4+、CD4+/CD8+水平、治疗后的生活质量、治疗结束1年内的生存情况、治疗期间的不良反应发生率。结果:治疗结束1周后,观察组患者的部分缓解(PR)、客观缓解率(ORR)和总疾病控制率(DCR)显著高于对照组患者(P<0.05),稳定(SD)和病情进展(PD)显著低于对照组患者(P<0.05)。治疗前,两组患者外周血中的CD3+、CD4+、CD4+/CD8+水平差异无统计学意义(P>0.05);治疗后,两组患者外周血中的CD3+、CD4+、CD4+/CD8+水平均有所上升,且观察组高于对照组(P<0.001)。治疗后,观察组患者在吞咽困难和进食受限症状领域的评分均显著低于对照组(P<0.05)。1年随访期间,观察组的疾病无进展生存期显著长于对照组[(7.42±0.89)个月 vs (5.35±0.68)个月,P<0.001]。两组患者在治疗期间的不良反应总发生率,差异无统计学意义(P>0.05)。结论:伊立替康联合乌苯美司方案治疗晚期胃癌的临床疗效更显著,可以提高患者的机体免疫功能,改善患者的生活质量,延长患者的无进展生存时间,安全性较高。

-----英文摘要:---------------------------------------------------------------------------------------

 [Abstract]  Objective  To analyze and compare the clinical efficacy and safety of irinotecan chemotherapy regimen and irinotecan combined with ubenimex chemotherapy regimen for the treatment of advanced gastric cancer. Methods  The clinical data of 104 patients with advanced gastric cancer admitted to Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology from January 2018 to January 2022 were retrospectively analyzed. According to the different treatment plans adopted by the patients, all the patients were divided into control group (irinotecan chemotherapy plan, n=61) and observation group (irinotecan combined with ubenimex treatment plan, n=43), and were treated with 21 days as 1 cycle for a total of 2 Cycle. The short-term clinical efficacy of the two groups at 1 week after treatment, the levels of CD3+, CD4+, CD4+/CD8+ in the peripheral blood before and after treatment, the quality of life after treatment, the survival within 1 year after the end of treatment, and the incidence of adverse reactions during treatment were compared. Results  One week after the end of treatment, the partial response (PR), objective response rate (ORR) and disease control rate (DCR) of patients in the observation group were significantly higher than those of patients in the control group (P<0.05), and the stable disease (SD) and progressive disease (PD) were significantly lower than those of patients in the control group (P<0.05). Before treatment, there were no statistically significant differences in the levels of CD3+, CD4+ and CD4+/CD8+ in the peripheral blood of the two groups (P>0.05), but after treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the peripheral blood of the two groups increased, and the observation group was higher than the control group (P<0.001). After treatment, patients in the observation group had significantly lower scores in the symptom domains of dysphagia and feeding restriction than those in the control group (P<0.05). During the 1-year follow-up, disease progression-free survival was significantly longer in the observation group than in the control group [(7.42±0.89) months vs. (5.35±0.68) months, P<0.001). Comparing the total incidence of adverse reactions during the treatment period between the two groups, there was no statistically significant difference (P>0.05). Conclusion  The clinical efficacy of irinotecan combined with ubenimex in the treatment of advanced gastric cancer is more significant, which can improve the immunity function of the patients, improve the quality of life of the patients, prolong the progression-free survival time of the patients, with higher safety.

-----参考文献:---------------------------------------------------------------------------------------

欢迎阅读《中华消化病与影像杂志(电子版)》!您是该文第 413 位读者!

若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式: 盛静1,梅勇2,夏佩3,王晓林4.乌苯美司联合伊立替康二线治疗晚期胃癌的临床研究.中华消化病与影像杂志(电子版).2023;1(5):317-321.
英文著录格式: .Clinical study of second-line treatment of advanced gastric cancer with ubenimex combined with irinotecan.No Title Settings.2023;1(5):317-321.

与该文相关的文章(仅限于本刊内

已投本刊未发表相似文章

地址:山东济南市槐荫区段兴西路4号,山东省第二人民医院《中华消化病与影像杂志(电子版)》编辑部;

邮政编码:250022;电话:0531-83086377;投稿邮箱:zhxhbyyxzz@126.com  鲁公网安备 37010402001170号

本系统由北京博思汇文数字科技有限公司设计开发 技术服务电话:010-60213898

鲁ICP备18044012号-6